Open Access

Erratum to: BCoR-L1variation and breast cancer

  • Felicity Lose1, 2,
  • Jeremy Arnold1,
  • David B Young1,
  • Carolyn J Brown3,
  • Graham J Mann4,
  • Gulietta M Pupo4,
  • The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer,
  • Kum Kum Khanna1,
  • Georgia Chenevix-Trench1 and
  • Amanda B Spurdle1Email author
Breast Cancer Research200810:406

https://doi.org/10.1186/bcr2153

Published: 21 October 2008

The original article was published in Breast Cancer Research 2007 9:R54

Following the publication of our article [1] we noticed that, due to a production error, the figure legends and images were incorrectly matched. All legends were correctly placed, and cited in the text, but were associated with the wrong image.

The figures should therefore appear in the order shown in this correction.
Figure 1

BcoR-L1 expression in cancer and normal cell lines. (a) BCoR-L1 expression in cancer and normal cell lines. (b) Mean and standard deviation of BCoR-L1 expression in cancer and normal cell lines. Normal cell lines: ovarian – OSE 64/96, HOSE 17.1; breast – SVCT, Bre80hTERT; prostate – RWPE1. BCoR-L1, BCL6 corepressor-like 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Figure 2

BCoR-L1 haplotype sharing family pedigree detailing carriers of the c.516T>C and c.3608-156C>T variants. = breast cancer-positive; c.516T>C and c.3608-156C>T-positive. = breast cancer-negative; c.516T>C and c.3608-156C>T-positive. = breast cancer-negative; c.516T>C and c.3608-156C>T-negative. = female, □ = male; subjects marked by small shapes were not available for genotyping. BCoR-L1, BCL6 corepressor-like 1.

Figure 3

BcoR-L1 expression in lymphoblastoid cell lines (LCLs) from breast cancer families. (a) BCoR-L1 expression in LCLs from breast cancer families (normalised to GAPDH). (b) BCoR-L1 expression in LCLs from breast cancer families (normalised to DIDO-1). (c) Mean and standard deviation of BCoR-L1 expression in samples, grouped according to type of family cancer or BCoR-L1 genotype (normalised to GAPDH). (d) Mean and standard deviation of BCoR-L1 expression in samples, grouped according to type of family cancer or BCoR-L1 genotype (normalised to DIDO-1). *Subject also carries a BRCA2 mutation. #Subjects from the same BCoR-L1 haplotype sharing family. BCoR-L1, BCL6 corepressor-like 1; DIDO-1, death inducer-obliterator 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Figure 4

Variation in control gene expression. (a) Variation in control gene expression in lymphoblastoid cell lines. (b) Variation in control gene expression in cell lines. DIDO-1, death inducer-obliterator 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; UBC, ubiquitin C.

Notes

Declarations

Authors’ Affiliations

(1)
Cancer and Cell Biology Division, Queensland Institute of Medical Research
(2)
School of Medicine, Central Clinical Division, University of Queensland, Royal Brisbane Hospital
(3)
Department of Medical Genetics, Molecular Epigenetics Group, University of British Columbia
(4)
Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital

References

  1. Lose F, Arnold J, Young DB, Brown CJ, Mann GJ, Pupo GM, The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Khanna KK, Chenevix-Trench G, Spurdle AB: BcoR-L1 variation and breast cancer. Breast Cancer Res. 2007, 9: R54-10.1186/bcr1759.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© BioMed Central Ltd 2008

Advertisement